An American Lung Association Edward Livingston Trudeau Scholar and recipient of the Cystic Fibrosis Foundation (CFF) LeRoy Matthew’s Physician-Scientist Award, Dr. Ferkol’s research has focused on characterizing genetic and molecular factors that contribute to airway disease in cystic fibrosis and primary ciliary dyskinesia with past and continued support from the National Institutes of Health (NIH), CFF and March of Dimes. He and his collaborators are currently examining the effects of viral infections on the microbiota, inflammation, lung function, and structural changes in the cystic fibrosis airway in infants, thus defining early pathogenic events in cystic fibrosis lung disease. (R01HL116211). He is an investigator for the NIH-supported Genetic Diseases of Mucociliary Clearance Consortium (U54HL096458), a clinical research network to study rare diseases of the airways. Dr. Ferkol is a member of a multidisciplinary research collaborative created at Washington University that defines clinical, functional, and structural phenotypes of patient subpopulations with known or suspected ciliopathies, a project funded by the Children’s Discovery Institute, studying the genetic and phenotypic spectrum of ciliopathies. Most recently, his efforts have turned to understand the long-term impact of physiological and structural changes in the lung lead on respiratory outcomes in children with chronic lung diseases related to prematurity (U01HL101465).
Thomas W. Ferkol, M.D.
Department of Pediatrics
Division of Pediatric Allergy and Pulmonary Medicine
at St Louis Children’s Hospital
Washington University School of Medicine
660 South Euclid, Box 8116
St. Louis, Missouri 63110
e-mail address: email@example.com